Quick Facts
AOD-9604 (Advanced Obesity Drug) is a modified peptide fragment derived from the C-terminus ofhuman Growth Hormone (hGH residues 177-191). Engineered specifically to isolate the fat-burningparameters of growth hormone without inducing unwanted anabolic side effects, it acts as aselective lipolytic agent. Administered under medical guidance, AOD-9604 offers a uniquetherapeutic approach focused on targeting localized adipose tissue reduction, stimulatingmetabolic rate, and supporting metabolic health without impacting blood glucose or insulinsensitivity.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide that belongs to a class of compounds known as triple receptor agonists. It is designed to activate three key metabolic hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.Retatrutide is being studied in metabolic and obesity-related research because of its unique multi-receptor mechanism of action. Unlike traditional single-pathway compounds, Retatrutide targets multiple metabolic signaling pathways that researchers believe may influence appetite regulation, energy expenditure, glucose metabolism, and body weight.Developed by Eli Lilly and Company, Retatrutide has become one of the most widely discussed investigational peptides in metabolic research and is currently being evaluated in ongoing clinical studies. Retatrutide is a novel triple agonist peptide targeting the GLP-1, GIP, and glucagon receptors simultaneously.
Retatrutide (LY3437943) is a novel investigational peptide developed by Eli Lilly and Company. It is classified as a triple agonist, meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-receptor engagement sets Retatrutide apart from every other metabolic research peptide currently in development or on the market.
As of 2023, Retatrutide has demonstrated unprecedented weight loss outcomes in Phase 2 clinical trials, with participants achieving a mean body weight reduction of up to 24.2% over 48 weeks — making it the most effective weight loss compound ever tested in a randomized controlled trial at the time of publication.
How Does Retatrutide Work?
Retatrutide works by binding to and activating three key metabolic hormone receptors in the body. Each receptor plays a distinct role in energy metabolism, appetite regulation, and glucose homeostasis. By engaging all three simultaneously, Retatrutide creates a synergistic effect that exceeds what any single or dual agonist can achieve.
Why Was Retatrutide Developed?
Retatrutide was developed to address the limitations of first and second generation metabolic peptides. While semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) demonstrated significant efficacy, researchers hypothesized that adding glucagon receptor activity could further enhance energy expenditure through thermogenesis and hepatic fat reduction.
What Receptors Does It Target?
- GLP-1 Receptor — Controls insulin secretion, slows gastric emptying, and signals satiety to the brain
- GIP Receptor — Enhances insulin sensitivity, augments GLP-1 effects, and modulates lipid metabolism
- Glucagon Receptor — Increases energy expenditure via thermogenesis and reduces hepatic fat accumulation
How Is Retatrutide Different From Other Peptides?
- Only peptide in development targeting GLP-1, GIP AND glucagon simultaneously
- Highest weight loss outcomes ever recorded in a randomized controlled trial (24.2%)
- Significant reduction in liver fat — addressing NAFLD and metabolic liver disease
- Improvements in cardiometabolic markers including blood pressure and lipid profiles
- Once-weekly subcutaneous injection with a favorable tolerability profile
GLP-1 Receptor
Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates satiety pathways in the hypothalamus to reduce food intake.
GIP Receptor
Enhances glucose-stimulated insulin secretion, improves insulin sensitivity in peripheral tissues, augments GLP-1 activity, and modulates lipid metabolism and adipose tissue function.
Glucagon Receptor
Increases hepatic glucose production, stimulates thermogenesis and energy expenditure, promotes lipolysis, and directly reduces liver fat — a key differentiator from GLP-1/GIP dual agonists.
The simultaneous activation of all three receptors creates a synergistic metabolic effect that exceeds single-receptor targeting alone.
AOD-9604 Research Studies
Published clinical and preclinical research on AOD-9604 .
AOD-9604 Clinical Trial Evaluations
- Human clinical trials assessing over 300 participants demonstrated significant weight loss patterns directly correlated with fat mass reduction./li> Treatment periods ranging from 12 to 24 weeks confirmed a steady reduction in body fat percentages, particularly in the abdominal area.
- AOD-9604 maintained an unblemished safety profile throughout all clinical trial phases, with no antibody formation or significant adverse reactions reported.
- Comparative analysis confirmed that unlike full hGH, AOD-9604 completely avoids inducing carbohydrate intolerance or altering fasting insulin.
AOD-9604 Cartilage and Regenerative Studies
- In vitro and in vivo models examining joint health revealed that AOD-9604 significantly stimulates the regeneration of compromised cartilage tissue.
- Co-administration trials indicated a synergistic effect when paired with hyaluronic acid, showing substantial improvements in joint functional recovery.
AOD-9604 Systemic Metabolic Findings
Extensive clinical research consistently highlights several secondary benefits of AOD-9604administration:
- No effect on serum growth factors or IGF-1 levels.
- Upregulation of beta-3 adrenergic pathways, triggering accelerated lipolysis.
- Complete lack of a hyperinsulinemic or hyperglycemic response.
- Favorable trends in overall systemic lipid profiles and fat cell reduction.
🔑 Key Finding: 24.2% weight loss at highest dose.
Retatrutide vs Other Peptides
How does Retatrutide compare to other leading research peptides?
| Feature | Semaglutide | Tirzepatide | Liraglutide |
|---|---|---|---|
| Weekly Injection | Yes | Yes | Daily |
| Appetite Control | Excellent | Excellent | Moderate |
| Average Weight Loss | 15-17% | 20%+ | 6-8% |
| Dosing Frequency | Weekly | Weekly | Daily |
| Blood Sugar Support | Yes | Yes | Yes |
| Long-Term Data | Extensive | Growing | Established |
| Convenience | High | High | Moderate |
Tirzepatide vs Semaglutide
- Tirzepatide may produce greater weight loss due to its dual-agonist mechanism (GIP + GLP-1).
- Semaglutide currently has longer-term weight management data available.
- Both medications require physician supervision and dose titration.
Tirzepatide vs Liraglutide
- Tirzepatide requires only weekly injections, whereas Liraglutide requires daily administration.
- Tirzepatide produces vastly superior weight reduction (20%+ compared to Liraglutide's 6-8%).
Testing & Monitoring
To ensure safety and measure metabolic progress, healthcare providers typically evaluate:
Medical History
MH- Comprehensive review of previous fat loss attempts and structural metabolic trends
- History of joint issues or severe connective tissue degradation
- Evaluation of concurrent medication regimens to rule out compound metabolic disruptions
Laboratory Testing
LT- Baseline Comprehensive Metabolic Panel (CMP)
- Fasting Blood Glucose and HbA1c to establish pre-treatment glycemic baseline
- Fasting Lipid panel (Total Cholesterol, HDL, LDL, Triglycerides)
- Baseline thyroid panel and hormone assessment if clinically indicated
Monitoring During Treatment
MDT- Changes in waist circumference, total weight, and overall body composition splits.
- Evaluation of systemic energy status and localized body composition response.
- Ongoing tracking of joint mobility and comfort improvements.
Frequently Asked Questions
Everything you need to know about peptide testing, certification, and compliance.
While initial metabolic activity shifts occur within days, visible modifications in body
composition and localized fat reduction typically develop over a 4 to 12-week window of
continuous daily administration.
No. Unlike central nervous system stimulants (such as phentermine or caffeine-based fat
burners), AOD-9604 does not affect blood pressure or heart rate, meaning it does not cause
jitters, anxiety, or energy crashes.
For optimal results, AOD-9604 is best administered on an empty stomach—typically in the
morning or several hours after the last meal—to maximize subcutaneous absorption and
prevent food-induced blunting of lipolysis.
Yes. Because AOD-9604 operates through localized fat cell pathways without interacting with
gut hormones, it can be combined with appetite-suppressing GLP-1 therapies to help protect
muscle tissue while accelerating fat reduction.
Yes. Lyophilized AOD-9604 powder should be stored in a cool environment. Once
reconstituted into a liquid state, it must be kept refrigerated between 2°C and 8°C to maintain
molecular stability and prevent degradation.
Certified Vendor Requirements
To qualify as a PeptideValidation.com Certified Vendor, companies must meet our rigorous multi-step testing and documentation standards. Certification is not bought — it is earned through independent verification.
🏆 Apply for CertificationTo qualify, vendors must:
-
Submit Batch Testing
Vendors must submit product samples for independent third-party lab testing before listing.
-
Pass Purity Requirements
All products must meet minimum purity thresholds verified by HPLC analysis.
-
Verify Identity via LC-MS
Molecular identity of each compound confirmed through liquid chromatography-mass spectrometry.
-
Maintain Full Documentation
COAs, batch records, and testing documentation must be publicly available on the vendor profile.
-
Undergo Quarterly Re-Testing
Certification requires mandatory re-testing every quarter to maintain active certified status.
Looking for Certified Peptide Sources?
Access our directory of independently reviewed and tested vendors who meet our rigorous testing and validation standards.
PeptideValidation.com is an independent testing and certification platform. We do not sell peptides or receive commission from vendors.
Access Certified Vendor DirectoryRelated Peptides
Tirzepatide
GLP-1 + GIP dual receptor agonist. FDA approved for type 2 diabetes and obesity management.
Learn More → 🧬GLP-1 AgonistSemaglutide
Gold standard GLP-1 receptor agonist. Marketed as Ozempic and Wegovy globally.
Learn More → ⚡Amylin AnalogueCagrilintide
Long-acting amylin analogue in Phase 3 trials as a combination therapy with semaglutide.
Learn More → 🔥Dual AgonistSurvodutide
GLP-1 + Glucagon dual agonist by Boehringer Ingelheim currently in Phase 3 clinical trials.
Learn More → 🏋️Dual AgonistMazdutide
GLP-1 + Glucagon dual agonist showing strong metabolic and weight loss outcomes in trials.
Learn More → 🩺Healing PeptideBPC-157
Body Protection Compound. Researched for tissue repair, gut healing, and accelerated recovery.
Learn More → 💪Recovery PeptideTB-500
Thymosin Beta-4 fragment. Researched for muscle recovery, flexibility, and anti-inflammatory effects.
Learn More →